v3.23.3
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Current assets:    
Cash and cash equivalents $ 64,791 $ 92,942
Short-term investments 37,617 149,877
Restricted cash 146 146
Accounts receivable 163 40,221
Inventories 6,591 1,586
Other current assets 9,388 10,308
Total current assets 118,696 295,080
Property and equipment, net 4,628 6,300
Operating lease assets 59,175 68,022
Other assets 6,289 7,018
Total assets 188,788 376,420
Current liabilities:    
Accounts payable 6,511 6,871
Accrued compensation 14,430 17,659
Accrued research and development expenses 23,968 24,992
Deferred revenue 11,611 8,000
Other current liabilities 22,569 21,394
Total current liabilities 79,089 78,916
Deferred revenue - long-term 73,929 77,000
Operating lease liabilities - long-term 48,508 58,064
Liability related to the sale of future revenues - long-term 33,252 30,236
Other long-term liabilities 4,848 5,564
Total liabilities 239,626 249,780
Commitments and contingencies (Note 8)
Stockholders' equity (deficit):    
Common stock - $0.0001 par value, 500,000 shares authorized as of September 30, 2023 and December 31, 2022; 101,922 and 95,927 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively 10 10
Additional paid-in capital 1,858,423 1,821,721
Accumulated other comprehensive (loss) income (571) (2,067)
Accumulated deficit (1,908,700) (1,693,024)
Total stockholders' equity (deficit) (50,838) 126,640
Total liabilities and stockholders' equity (deficit) $ 188,788 $ 376,420

Source